Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07673081

Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos

Among non-pregnant adults observed in Epic Cosmos since August 2023 who are eligible for RSV vaccination, what is the effectiveness of ABRYSVO® (RSVpreF), compared with unvaccinated individuals, in preventing RSV-related and all-cause acute respiratory illness (ARI), lower respiratory tract disease (LRTD), and other outcomes of interest, within a target trial emulation (TTE) framework

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion: Vaccinated Cohort

Patients must meet all the following inclusion criteria to be eligible for inclusion in the vaccinated cohort:

Adults meet the age criteria at the index date. Non-pregnant at the index date. Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date.

Have a documented administration of ABRYSVO® (or AREXVY®,mRESVIA® in the later phase) in Epic Cosmos on or after August 2023.

The index date for vaccinated individuals will be defined as the date of RSV vaccination.

Unvaccinated Cohort

Patients must meet all the following inclusion criteria to be eligible for inclusion in the unvaccinated cohort:

Adults meet the age criteria at the index date. Non-pregnant at the index date. Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date.

Have no documented receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date.

The index date for unvaccinated individuals will be defined as the start date of each sequential trial (e.g., 1st date of each month) in which they met eligibility criteria.

Exclusion:

Vaccinated Cohort

Patients meeting any of the following criteria will not be included in the vaccinated cohort:

Individual with receipt of any RSV vaccine in Epic Cosmos prior to the trial start date, as defined above (applicable to all analyses except for the analysis of recipients of multiple doses).

Non-US residents. Unvaccinated Cohort

Patients meeting any of the following criteria will not be included in the unvaccinated cohort:

Individual with receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date, as defined above.

Non-US residents. Patients must meet all the inclusion criteria and none of the exclusion criteria to meet eligibility requirements.

Treatment and study plan

Primary outcomes

  1. Incidence of RSV-related Acute Respiratory Infection (ARI) hospitalization

    Time frame: up to 3 years

  2. Incidence of RSV-related Lower Respiratory Tract Disease (LRTD) hospitalization

    Time frame: up to 3 years

Secondary outcomes

  1. Incidence of RSV-related outcomes

    Time frame: up to 3 years

    ARI/LRTD non-inpatient encounter, ARI/LRTD severe outcome, ARI/LRTD critical outcome, CV events with different care settings, thromboembolic event with different care settings, asthma exacerbation with different care settings, COPD exacerbation with different care settings, and pneumonia with different care settings.

  2. Incidence of All-cause outcomes

    Time frame: up to 3 years

    all-cause ARI/LRTD encounter with different care settings, severe outcome, critical outcome, CV events with different care settings, thromboembolic event with different care settings, asthma exacerbation with different care settings, COPD exacerbation with different care settings, pneumonia with different care settings, and dementia (new onset).

Study contacts

Contact information is provided by the study sponsor or research team.

Pfizer CT.gov Call Center

CONTACT

[email protected]

1-800-718-1021

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Collaborators

  • Ividence

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jun 29, 2026
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.